Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (73 News)
Country: Germany · Primary market: Germany · EQS NID: 1796915
14 December 2023 10:09AM

CGM registers significant increase in issued e-prescriptions


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous
CGM registers significant increase in issued e-prescriptions

14.12.2023 / 10:09 CET/CEST
The issuer is solely responsible for the content of this announcement.


CGM registers significant increase in issued e-prescriptions

Koblenz. The digitization of the German healthcare system is gaining more momentum: Last week, 715,000 e-prescriptions were issued in the Ambulatory Information Systems of CompuGroup Medical (CGM) alone. This represents an increase of 45 percent compared to the previous week. In the two-month period to and including December 10, a total of 2.7 million e-prescriptions were issued via CGM's Ambulatory Information Systems. E-prescriptions are redeemed via electronic health card, gematik app, CGM's CLICKDOC mobile solution, or by printing the data matrix code. 

"The strong increase of e-prescriptions shows: The digitization of the German healthcare system is making significant progress. With electronic prescriptions, it is now reaching all patients. CompuGroup Medical is driving this development in many ways. We are currently working intensively to support practice teams in introducing e-prescriptions and setting up convenient signature procedures. We offer a wide range of consulting services for new processes in the interaction between practices and software. Our core understanding is to be a partner at the physician's side," says Dr. Ulrich Thomé, Managing Director Ambulatory Information Systems DACH at CGM.

Dr. Beatrice Staudt, general practitioner and CGM user from Berlin, comments on the electronic prescription as follows: "Electronic prescribing significantly accelerates practice processes. It leads to greater safety in patient care. It takes the pressure off my practice team and our patients. I am pleased that digitization is advancing in the healthcare sector. The electronic doctor's letter and video consultation have also proved to be particularly helpful in my practice."

According to gematik, a total of 13.3 million e-prescriptions have now been issued in Germany. The number has more than doubled in the last two months. The amount of medical facilities that issue e-prescriptions on a weekly basis has also more than doubled and currently stands at 35,000. 17,300 - almost all - pharmacies accepted e-prescriptions last week.



14.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1796915

 
End of News EQS News Service

1796915  14.12.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1796915&application_name=news&site_id=boersengefluester_html
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.